MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer

Overview

Journal Cardiovasc Intervent Radiol

Specialty Cardiology & Vascular Diseases

Date 2024 Mar 16

PMID 38491163

Authors

Kin Fen Kevin Fung

Roberto Luigi Cazzato

Thibault Tricard

Pierre D E Marini

Gregory Bertucci

Pierre-Alexis Autrusseau

Guillaume Koch

Julia Weiss

Julien Garnon

Herve Lang

Afshin Gangi

Affiliations

Soon will be listed here.

Abstract

The optimal treatment strategy for men with localised prostatic cancer of low and intermediate risk is an actively evolving field. It is important to strike a balance between maximal oncological control and minimal treatment-related complications, which helps preserve the patients' quality of life. MR-guided transurethral ultrasound ablation (TULSA) has emerged as a minimally invasive treatment option for this group of patients. This article aims to provide of a background on TULSA technology, a step-by-step procedural guide of MR-guided TULSA and to summarise the current evidence of TULSA in management of localised prostatic cancer, as well as other potential indications.

References

Culp M, Soerjomataram I, Efstathiou J, Bray F, Jemal A . Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2019; 77(1):38-52. DOI: 10.1016/j.eururo.2019.08.005. View

Klotz L . Overdiagnosis in urologic cancer : For World Journal of Urology Symposium on active surveillance in prostate and renal cancer. World J Urol. 2021; 40(1):1-8. DOI: 10.1007/s00345-020-03523-2. View

Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020; 79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. View

Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A . Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2009; 28(1):126-31. DOI: 10.1200/JCO.2009.24.2180. View

Eastham J, Auffenberg G, Barocas D, Chou R, Crispino T, Davis J . Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022; 208(1):10-18. DOI: 10.1097/JU.0000000000002757. View

Deivasigamani S, Kotamarti S, Rastinehad A, Salas R, de la Rosette J, Lepor H . Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023; 84(6):547-560. DOI: 10.1016/j.eururo.2023.06.013. View

Hopstaken J, Bomers J, Sedelaar M, Valerio M, Futterer J, Rovers M . An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?. Eur Urol. 2021; 81(1):5-33. DOI: 10.1016/j.eururo.2021.08.005. View

Chin Y, Lynn N . Systematic Review of Focal and Salvage Cryotherapy for Prostate Cancer. Cureus. 2022; 14(6):e26400. PMC: 9333556. DOI: 10.7759/cureus.26400. View

Anttinen M, Sequeiros R, Bostrom P, Taimen P . Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques. Front Oncol. 2022; 12:1043688. PMC: 9714456. DOI: 10.3389/fonc.2022.1043688. View

10.

Borges R, Tourinho-Barbosa R, Glina S, Macek P, Mombet A, Sanchez-Salas R . Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence. J Urol. 2020; 205(1):129-136. DOI: 10.1097/JU.0000000000001327. View

11.

Ahmed H, Dickinson L, Charman S, Weir S, McCartan N, Hindley R . Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. Eur Urol. 2015; 68(6):927-36. DOI: 10.1016/j.eururo.2015.01.030. View

12.

Huber P, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M . Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World J Urol. 2020; 39(4):1115-1119. PMC: 8124043. DOI: 10.1007/s00345-020-03297-7. View

13.

Klotz L, Pavlovich C, Chin J, Hatiboglu G, Koch M, Penson D . Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2020; 205(3):769-779. DOI: 10.1097/JU.0000000000001362. View

14.

Sundaram K, Staruch R, Burtnyk M, Lane J, Penson D, Arora S . MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. J Vasc Interv Radiol. 2020; 31(5):740-746.e4. DOI: 10.1016/j.jvir.2019.12.802. View

15.

Chin J, Billia M, Relle J, Roethke M, Popeneciu I, Kuru T . Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. Eur Urol. 2016; 70(3):447-55. DOI: 10.1016/j.eururo.2015.12.029. View

16.

Nair S, Hatiboglu G, Relle J, Hetou K, Hafron J, Harle C . Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. BJU Int. 2020; 127(5):544-552. DOI: 10.1111/bju.15268. View

17.

Peters I, Hensen B, Glandorf J, Gutberlet M, Dohna M, Struckmann S . First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study. BMC Urol. 2023; 23(1):142. PMC: 10464407. DOI: 10.1186/s12894-023-01306-6. View

18.

Burtnyk M, Hill T, Cadieux-Pitre H, Welch I . Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup. J Urol. 2014; 193(5):1669-75. DOI: 10.1016/j.juro.2014.11.089. View

19.

Rieke V, Pauly K . MR thermometry. J Magn Reson Imaging. 2008; 27(2):376-90. PMC: 2780364. DOI: 10.1002/jmri.21265. View

20.

Boyes A, Tang K, Yaffe M, Sugar L, Chopra R, Bronskill M . Prostate tissue analysis immediately following magnetic resonance imaging guided transurethral ultrasound thermal therapy. J Urol. 2007; 178(3 Pt 1):1080-5. DOI: 10.1016/j.juro.2007.05.011. View